Oppenheimer Asset Management Inc. Buys New Stake in Core Laboratories Inc. $CLB

Oppenheimer Asset Management Inc. purchased a new stake in Core Laboratories Inc. (NYSE:CLB) during the second quarter, according to its most recent filing with the SEC. The fund purchased 47,664 shares of the oil and gas company’s stock, valued at approximately $555,000.

Several other hedge funds have also bought and sold shares of CLB. CWM LLC boosted its holdings in shares of Core Laboratories by 36.1% during the 4th quarter. CWM LLC now owns 2,516 shares of the oil and gas company’s stock valued at $40,000 after purchasing an additional 668 shares during the last quarter. Platinum Investment Management Ltd. increased its holdings in shares of Core Laboratories by 3.9% in the third quarter. Platinum Investment Management Ltd. now owns 23,758 shares of the oil and gas company’s stock worth $294,000 after purchasing an additional 889 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Core Laboratories by 6.2% in the second quarter. The Manufacturers Life Insurance Company now owns 17,932 shares of the oil and gas company’s stock worth $207,000 after purchasing an additional 1,040 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Core Laboratories by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,893 shares of the oil and gas company’s stock worth $418,000 after buying an additional 1,170 shares in the last quarter. Finally, Quarry LP lifted its position in shares of Core Laboratories by 118.1% in the third quarter. Quarry LP now owns 2,953 shares of the oil and gas company’s stock worth $36,000 after buying an additional 1,599 shares in the last quarter. Hedge funds and other institutional investors own 97.81% of the company’s stock.

Insider Buying and Selling

In other news, CEO Lawrence Bruno acquired 5,000 shares of Core Laboratories stock in a transaction that occurred on Friday, July 31st. The shares were bought at an average cost of $10.78 per share, with a total value of $53,900.00. Following the transaction, the chief executive officer directly owned 262,438 shares of the company’s stock, valued at $2,829,081.64. This trade represents a 1.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Insiders own 1.26% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CLB shares. Johnson Rice raised Core Laboratories from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Thursday, August 13th. Wall Street Zen raised Core Laboratories from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Weiss Ratings raised Core Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, August 3rd. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Core Laboratories Stock Up 1.5%

Shares of CLB opened at $12.64 on Tuesday. The company has a market cap of $579.92 million, a PE ratio of 22.57, a P/E/G ratio of 3.00 and a beta of 1.03. The business has a fifty day moving average of $11.59 and a 200 day moving average of $14.62. Core Laboratories Inc. has a 52-week low of $9.79 and a 52-week high of $20.36. The company has a quick ratio of 1.55, a current ratio of 2.12 and a debt-to-equity ratio of 0.41.

Core Laboratories (NYSE:CLB) last posted its quarterly earnings data on Wednesday, July 29th. The oil and gas company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Core Laboratories had a net margin of 5.10% and a return on equity of 10.03%. The business had revenue of $124.61 million for the quarter, compared to analysts’ expectations of $126.26 million. During the same quarter in the previous year, the business posted $0.19 earnings per share. The business’s revenue was down 4.3% compared to the same quarter last year. Core Laboratories has set its Q3 2026 guidance at 0.120-0.200 EPS. On average, sell-side analysts expect that Core Laboratories Inc. will post 0.53 EPS for the current year.

Core Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Monday, August 10th will be issued a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, August 10th. Core Laboratories’s dividend payout ratio is presently 7.14%.

Core Laboratories Profile

Core Laboratories N.V. is a global provider of proprietary and patented reservoir description and production enhancement services to the oil and gas industry. The company applies specialized expertise in core and fluid analysis, advanced petrophysical interpretation, and reservoir engineering to optimize hydrocarbon recovery. By integrating laboratory testing with field services and digital analytics, Core Laboratories delivers insights that help operators maximize production and extend the life of their assets.

The company’s portfolio spans two primary service lines: reservoir description and production enhancement.